New York Blood Center, Inc.

The Rockefeller University

Jay E Valinsky

Bernard Horowitz

Bolanle Williams

Nicholas E Geacintov

Shanti B Rywkin

Henrietta Nunno

Edward Reich

Thomas G Easton

The present invention concerns a process for inactivating an extracellular lipid enveloped human pathogenic virus and/or an intracellular human pathogenic virus which may be present in a blood cell composition containing &gE;1&times;10,cells/ml by contacting that composition with a virucidally effective amount of at least one photoreactive compound having an absorption maximum of &gE;630 nm, light and oxygen and/or a quencher. In one embodiment of the invention, the process is conducted under conditions whereby a structural integrity of greater than 80% of at least one type of blood cell contained within said composition is retained. Another embodiment of the invention relates to a process for inactivating an extracellular lipid enveloped human pathogenic virus and/or an intracellular human pathogenic virus which may be present in a composition containing at least one coagulation factor while retaining at least 77% of said coagulation factor by contacting said composition with a virucidally effective amount of at least one photoreactive compound, light and a quencher. The processes of the invention can be used to prepare blood products, which, in turn, are suitable for transfusion into a recipient in need of such transfusion.

Processes for photoreactive inactivation of a virus in blood cell or coagulation factor containing compositions and use thereof for preparing compositions useful for transfusion

The present invention concerns the product produced by inactivating extracellular lipid enveloped pathogenic virus or intracellular pathogenic virus in a composition containing &gt;1.times.10.sup.9 cells/ml and said virus without incurring substantial disruption or inactivation of such cells, the inactivation process comprising contacting the composition with a virucidally effective amount of at least one photoreactive compound having an absorption maximum of .gtoreq.630 nm, light and an oxidizer, thereby substantially to inactivate the virus with retention of cell functionality, greater than 80%. The present invention also concerns the product produced by inactivating virus in a biological composition without incurring substantial disruption or inactivation thereof, the inactivation process comprising contacting said composition with a virucidally effective amount of at least one photoreactive compound, light, and a quencher thereby to inactivate said virus while retaining functionality of said substance.

Photodynamic inactivation of viruses in cell-containing compositions

The present invention concerns a method of inactivating extracelluar lipid enveloped human pathogenic virus or intracelular human pathogenic virus in a blood cell-containing composition without incurring substantial disruption or inactivation of cells, comprising contacting a cell-containing composition having .gtoreq.1.times.10.sup.9 cells/ml and containing infectious virus with a virucidally effective amount of at least one photoreactive compound having an absorption maximum of .gtoreq.630 nm, light and an oxidizer to substantially inactivate the virus to effect a virus kill of at least 10.sup.4 and to result in a retention of intact cell functionality and structure of greater than 80%. The present invention also is directed to a composition comprising human red blood cells suitable for transfusion at a concentration of .gtoreq.1.times.10.sup.9 cells/ml and having all extracellular lipid enveloped and intracellular human pathogenic viruses in a non-infectious form.

Photodynamic inactivation of viruses in blood cell-containing

A process of inactivating infectious viruses in a cell-containing or a protein-containing composition containing such viruses, comprising contacting such composition with an effective amount of at least one aryl diol epoxide of the formula ##STR1## in which X is an aromatic ring system having from 3 to 6 used rings, for a sufficient period of time substantially to inactivate said viruses without incurring substantial disruption or inactivation of cells or without incurring substantial protein denaturation.

Inactivation of viruses in cell- and protein-containing compositions

A method for the detection of malignant leukocytic cells which comprises:

Growing community of inventors

New York, NY, United States of America

Jay E Valinsky